CXCR3 and neoplasm: Researchers had identified CXCR3+CD8+T cells and CD11c+ antigen-presenting cells in TME through single-cell sequencing and genomic analysis, and explored the application of circulating tumor DNA (ctDNA) in efficacy monitoring (48, 49).